Mergers

Rallybio holders approve Avenzo merger and a self-growing stock plan, with about 21% voting against the plan

RLYB

The equity plan starts at 18% of the combined company and can add 5% of fully diluted shares each year to 2036. Rallybio holders take a $13.90 a share cash payout and keep about 2.8%.

Investor Chat

Scorecard

RLYB
Investor Impact: 9/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Investment Attractiveness: 5.7/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Mixed

By the aibio.space news desk

Assorted tablets and capsules
Assorted tablets and capsules. Photo: Pixabay, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

Rallybio Corporation's stockholders approved its reverse merger with Avenzo Therapeutics on November 4, 2026, and with it a stock plan built to grow every year for a decade. The new equity plan starts at 18% of the combined company's shares and adds up to 5% of fully diluted shares each January from 2027 through 2036. It drew the heaviest opposition of the meeting: 958,257 votes against and 3,564,394 for, so about 21% of shares voting either way said no. Under the proxy's estimates, Rallybio's existing holders will own about 2.8% of the combined company. Chief Financial Officer Jonathan I. Lieber signed the filing. Nov 4 8-K

The votes

The merger agreement, dated May 31, 2026, has Farmington Merger Sub, Inc. merging into Avenzo, which becomes a wholly owned subsidiary of Rallybio. Of 5,312,584 shares entitled to vote on the September 11, 2026 record date, 4,790,320 were represented. The share issuance to Avenzo holders, which passes the 20% threshold and changes control under Nasdaq Listing Rules 5635(a) and 5635(b), passed 4,506,703 to 15,979. Holders approved a reverse split range of 1-for-2 to 1-for-9, to be set by Rallybio and Avenzo together, a name change to Avenzo Therapeutics, Inc., and an increase in authorized common stock from 200,000,000 to 500,000,000 shares. The authorized share increase drew 245,991 votes against. Nov 4 8-K

Stephen Uden, Helen M. Boudreau, Lucian Iancovici and Christine A. Nash were elected as Class II directors. The filing notes that the vote counts for little if the merger closes, because the combined board will then be reconstituted under the merger agreement. The employee stock purchase plan passed 3,760,074 to 752,717. Nov 4 8-K

How the plan grows

The Avenzo Therapeutics, Inc. 2026 Equity Incentive Plan takes effect the day after the merger closes and replaces Rallybio's 2021 plan. The initial reserve equals 18% of the common stock outstanding immediately after the merger, and it includes shares that come back from 2021 plan awards that expire, are forfeited, are settled in cash or are withheld for taxes or exercise prices. On each January 1 from 2027 through 2036, the reserve rises by 5% of the Fully Diluted Shares on the prior December 31 unless the board picks a smaller number first. Fully Diluted Shares counts common stock plus preferred stock as converted, equity awards, warrants including pre-funded warrants, and convertible debt, vested or not. So each top-up can be larger than one based on common stock alone. Nov 4 8-K

Two other terms widen the plan. Shares issued in a merger or acquisition under listing rules, including Nasdaq Listing Rule 5635(c), do not count against the reserve. The cap on incentive stock options is three times the initial reserve. The plan adds shares to the reserve, and holders are diluted only as awards are granted and issued. The 8-K gives no share count for the 18%. Nov 4 8-K

The Avenzo 2026 Employee Stock Purchase Plan starts at 1% of the stock expected to be outstanding after the merger. On each January 1 from 2027 through 2036 it adds the lesser of 1% of Fully Diluted Shares and three times the initial reserve, unless the board sets a smaller amount or none. Both plans were filed by reference to Exhibits 10.16 and 10.17 of the Form S-4 filed on July 15, 2026. Nov 4 8-K

Cash out, then dilution

Before the merger, Rallybio is paying out its cash. The board set the special cash distribution at $83.6 million, or $13.90 per share, up from the $82.7 million, or $13.56 per share, estimated on October 26. It is payable to holders of record on November 5, 2026, with payment due to start on November 13. Nasdaq has advised that the stock trades with due bills through the close on November 6, ahead of an expected ex-dividend date of November 9. The company expects the merger to close on November 6. Rallybio and Avenzo do not plan to do the reverse split before closing. Nov 4 8-K, Oct 26 8-K

The proxy statement says that after the merger and a $215.0 million concurrent private placement, Avenzo's pre-merger holders will own about 56.6% of the combined company, the placement investors about 40.6%, and Rallybio's pre-merger holders about 2.8%. Those figures rest on a $15.0 million valuation for Rallybio after the cash payout and $300.0 million for Avenzo. Avenzo is a clinical-stage oncology company with four clinical-stage candidates: selective CDK inhibitors and bispecific antibody-drug conjugates. Rallybio holders also receive contingent value rights, and the 8-K warns those may never pay anything. Proxy statement, Nov 4 8-K

What to watch

The closing filing should confirm the merger, the final reverse split ratio and the share count that sets the plan's 18% reserve. The 8-K also lists as a risk that the concurrent financing may not close. Nov 4 8-K

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.